Table1.
CpG sites associated with glycemic traits in discovery phase
| Locus | CpG | Chr: Pos | Trait | BetaM1 | P valueM1 | BetaM2 | P valueM2 |
|---|---|---|---|---|---|---|---|
| FCRL6 | cg00936728 | 1: 159772194 | Glucose | −1.79 | 9.1 × 10−8ǂ | −1.60 | 1.9 × 10−7 |
| SLAMF1 | cg18881723 | 1: 160616870 | Glucose | 1.16 | 7.5 × 10−8ǂ | 1.25 | 3.4 × 10−10ǂ |
| 1q25.3 | cg13222915 | 1: 184598594 | Insulin | −1.69 | 2.6 × 10−9ǂ | −1.06 | 4.1 × 10−6 |
| BRE | cg20657709 | 2: 28509570 | Glucose | −1.42 | 2.7 × 10−6 | −1.53 | 4.1 × 10−8ǂ |
| LRPPRC | cg01913188 | 2: 44223249 | Glucose | 1.18 | 9.4 × 10−6 | 1.38 | 5.7 × 10−9ǂ |
| IRAK2 | cg14527942 | 3: 10276383 | Insulin | 2.44 | 3.4 × 10−10ǂ | 2.14 | 2.9 × 10−11ǂ |
| LETM1 | cg13729116 | 4: 1859262 | Insulin | 2.38 | 4.3 × 10−8ǂ | 1.64 | 4.5 × 10−6 |
| RBM20 | cg15880704 | 10: 112546110 | Insulin | 2.50 | 3.8 × 10−9ǂ | 1.38 | 6.7 × 10−5 |
| IRS2 | cg25924746 | 13: 110432935 | Insulin | 2.11 | 3.0 × 10−9ǂ | 1.32 | 4.9 × 10−6 |
| SPTB | cg07119168 | 14: 65225253 | Glucose | −1.64 | 4.4 × 10−7 | −1.63 | 4.9 × 10−8ǂ |
| 15q26.1 | cg18247172 | 15: 91370233 | Glucose | −1.05 | 4.9 × 10−6 | −1.18 | 2.8 × 10−8ǂ |
| MAN2A2 | cg20507228 | 15: 91460071 | Insulin | 1.18 | 5.5 × 10−8ǂ | 0.87 | 9.0 × 10−7 |
| FAM92B | cg06709610 | 16: 85143924 | Insulin | 6.22 | 6.5 × 10−9ǂ | 6.30 | 5.8 × 10−13ǂ |
| CD300A | cg08087047 | 17: 72461209 | Glucose | −1.35 | 5.9 × 10−6 | −1.45 | 1.1 × 10−7ǂ |
| APOBEC3H | cg06229674 | 22: 39492189 | Glucose | −1.62 | 1.8 × 10−6 | −1.70 | 4.7 × 10−8ǂ |
Novel epigenome-wide significant results in the discovery phase (n = 4808) are shown. Model 1 (M1) indicates inverse variance-weighted fixed effect meta-analysis of effect estimates in four cohorts. Each cohort performed a regression model adjusting for age, sex, technical covariates, white blood cell, and smoking status, and accounting for family structure in family-based cohorts. Model 2 (M2) indicates the meta-analysis of the same studies, adjusting for body mass index (BMI) additionally. Locus: the cytogenetic location or the gene symbol of the CpG sites from Illumina annotation. Beta: effect estimate of the meta-analysis. P value shown is genomic controlled after meta-analysis. The effect refers to the increase/ decrease in fasting glucose/ insulin as the outcome in the model
ǂSignificant results (P value < 1.3 × 10−7)